SCHEMBL23966711

SCHEMBL23966711

CC(C)(C)c1cc(C2(C(F)(F)F)CC2)no1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HPGD P15428 1/20 0.35
EGFR P00533 3/20 0.35
NPC1 O15118 3/20 0.34
RAB9A P51151 2/20 0.34
CNR2 P34972 4/20 0.33
CNR1 P21554 3/20 0.33
EPHX2 P34913 2/20 0.33
MAPK14 Q16539 2/20 0.33
SMN1; SMN2 Q16637 3/20 0.32
TDP1 Q9NUW8 1/20 0.32
BRD4 O60885 1/20 0.31
LMNA P02545 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23966641 0.93 MEN1 (0.36) MEN1KMT2AHPGDEGFRNPC1
SCHEMBL23966740 0.84
SCHEMBL23966823 0.82 NEK7 (0.30)
SCHEMBL23966690 0.77 MEN1 (0.44) MEN1KMT2AHPGDEGFRNPC1
SCHEMBL25802867 0.76 BRAF (0.32)
SCHEMBL23966920 0.76 SMN1; SMN2 (0.33) NPC1RAB9ASMN1; SMN2
SCHEMBL16536514 0.75 NEK7 (0.32)
SCHEMBL23966700 0.75 MEN1 (0.37) MEN1KMT2AHPGDEGFRNPC1
SCHEMBL23966699 0.74 MEN1 (0.42) MEN1KMT2AHPGDEGFRNPC1
SCHEMBL25792548 0.73 MEN1 (0.36) MEN1KMT2AHPGDEGFRNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 US disclosed
US-11713321-B2 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2023-08-01 US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 US disclosed
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME Halia Therapeutics, Inc. 2023-07-06 US disclosed
US-20230203045-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2023-06-29 US disclosed
WO-2021252488-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. (US) 2021-12-16 WO disclosed
US-20210355130-A1 INHIBITORS OF NEK7 KINASE Halia Therapeutics, Inc. 2021-11-18 US disclosed
US-11161852-B1 Inhibitors of NEK7 kinase Halia Therapeutics, Inc. (US) 2021-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210355130-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 MEN1 1766/4885KMT2A 2554/4885HPGD 2524/4885
US-20230203045-A1 INHIBITORS OF NEK7 KINASE NEK7, NEK1, NEK5 MEN1 1800/4885KMT2A 2881/4885HPGD 2484/4885
US-11713321-B2 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 MEN1 1766/4885KMT2A 2554/4885HPGD 2524/4885
US-20230210853-A1 TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME NEK7, NLRP3, NOD1 MEN1 3098/4885KMT2A 4530/4885HPGD 1303/4885
US-11161852-B1 Inhibitors of NEK7 kinase NEK7, NEK1, NEK5 MEN1 1766/4885KMT2A 2554/4885HPGD 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.